Experimental drug targets Notch-Activated cancer before surgery
NCT ID NCT04973683
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 1 trial tested the drug AL101 in 13 people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (notch activation). Participants received AL101 before their standard surgery to see if it is safe and might help control the cancer. The study focused on side effects and changes in tumor markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AL101 (a drug that blocks notch pathway enzymes)
- What this could lead to
- If it works, this could point toward a new treatment option for adenoid cystic carcinoma with notch activation.
- What could go wrong
- This is a very early phase 1 trial with only 13 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a targeted drug shrink rare salivary gland tumors?
- New drug cocktail targets genetic weakness in rare cancer
- Drug duo takes on rare head and neck tumors
- Rare sinus cancer study aims to clarify treatment outcomes
- New pill-chemo combo takes on hard-to-treat cancers